<SEC-DOCUMENT>0001516551-24-000059.txt : 20240610
<SEC-HEADER>0001516551-24-000059.hdr.sgml : 20240610
<ACCEPTANCE-DATETIME>20240610092739
ACCESSION NUMBER:		0001516551-24-000059
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240610
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240610
DATE AS OF CHANGE:		20240610

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Skye Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42009
		FILM NUMBER:		241031612

	BUSINESS ADDRESS:	
		STREET 1:		11250 EL CAMINO REAL, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 410-0266

	MAIL ADDRESS:	
		STREET 1:		11250 EL CAMINO REAL, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Emerald Bioscience, Inc.
		DATE OF NAME CHANGE:	20190325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nemus Bioscience, Inc.
		DATE OF NAME CHANGE:	20141030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>skye-20240610.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5b56f1a-30f4-4661-b175-1f0050784193,g:1ece6a67-4871-47f8-9d23-a4b267bd419c,d:15ef64880ee241c89c108aedaa452ed0-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>skye-20240610</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-19">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-20">0001516551</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="skye-20240610.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-10</xbrli:startDate><xbrli:endDate>2024-06-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i15ef64880ee241c89c108aedaa452ed0_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">June 10, 2024</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.993%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">SKYE BIOSCIENCE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.993%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.018%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.018%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-55136</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">45-0692882</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">11250 El Camino Real</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 100</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">92130</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Address of principal executive offices)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">410-0266</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:100pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.826%"><tr><td style="width:1.0%"/><td style="width:31.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name of each exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Common Stock, par value $0.001</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SKYE</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nasdaq Global Market</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i15ef64880ee241c89c108aedaa452ed0_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 8.01 Other Events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2024, Skye Bioscience, Inc. (the &#8220;Company,&#8221; &#8220;we&#8221; and &#8220;our&#8221;) issued a press release announcing that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion (&#8220;OE&#8221;) in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering intraocular pressure. The Company intends to discontinue the clinical development of SBI-100 OE and all research and development associated with SBI-100 including its ophthalmology pipeline to direct its clinical development resources to its obesity program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The press release will also be available under the &#8220;Investors&#8221; section of the Company&#8217;s website. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD LOOKING STATEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development, business strategy, the timing of clinical trials and published findings, and expected operating runway. Such statements and other statements in this Current Report on Form 8-K that are not descriptions of historical facts are forward-looking statements that are based on management&#8217;s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including &#8220;anticipated,&#8221; &#8220;plans,&#8221; &#8220;goal,&#8221; &#8220;focus,&#8221; &#8220;aims,&#8221; &#8220;intends,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;challenge,&#8221; &#8220;predictable,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;may&#8221; or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company&#8217;s periodic filings with the Securities and Exchange Commission, including in the &#8220;Risk Factors&#8221; section of Skye&#8217;s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a240610_skyexnrxsbip2atopl.htm">Press Release</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i15ef64880ee241c89c108aedaa452ed0_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.859%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SKYE BIOSCIENCE, INC.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: June 10, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/s/&#160; Punit Dhillon</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: Punit Dhillon</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: Chief Executive Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a240610_skyexnrxsbip2atopl.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia59118ad8d3747669754828109f30375_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:112%"> Skye Concentrates Strategy and Clinical Development Focus on </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Nimacimab Metabolic Program</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">SBI-100 Ophthalmic Emulsion Phase 2a trial does not achieve target product profile&#59;     program discontinued </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Phase 2 study of Nimacimab in obesity expected to start in Q3 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Cash runway extended into 2027</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SAN DIEGO, June 10</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> 2024 &#8211; Skye Bioscience, Inc. (</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Nasdaq</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58; SKYE) (&#34;Skye&#34; or the &#34;Company&#8221;), </font><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, announced that its Phase 2a clinical trial of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SBI-100 Ophthalmic Emulsion (&#34;OE&#34;) </font><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">in patients with </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">primary open-angle glaucoma (&#34;POAG&#34;) or ocular hypertension (&#34;OHT&#34;) </font><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">did not meet its primary endpoint </font><font style="color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">for lowering intraocular pressure (&#8220;IOP&#8221;)</font><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Skye intends to discontinue clinical development and spending related to SBI-100 OE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">and any R&#38;D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027. Skye&#8217;s Phase 2 obesity clinical trial for its differentiated CB1 inhibitor, Nimacimab, is expected to begin dosing in Q3 2024.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this Phase 2a </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">double-masked, randomized, placebo-controlled </font><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">trial of SBI-100 OE, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56 patients with elevated IOP diagnosed with POAG or OHT received dosing of 1.0% or 0.5% concentrations of SBI-100 OE, or placebo, consisting of one drop in each eye, twice a day, for 14 days. </font><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary endpoint was to assess change in diurnal intraocular pressure in the treated arms vs. placebo. The study did not achieve a statistically significant improvement in IOP over placebo. The drug was safe and a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ll treated patients completed the study</font><font style="background-color:#ffffff;color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with no </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">early discontinuations due to adverse events.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The results of this Phase 2a clinical trial of SBI-100 OE unfortunately did not meet our pre-set criteria for continuation and further development of this molecule as an alternative treatment for glaucoma and ocular hypertension. We will continue to evaluate the full data set and intend to publish findings,&#8221; said Tu Diep, Skye&#8217;s Chief Development Officer. &#8220;We thank the patients and investigators who supported our clinical investigation of SBI-100 OE in this study.&#8221;</font><font style="color:#18193f;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;In the last year we laid the groundwork for our metabolic program with the goals of diversifying our product portfolio&#8217;s  disease targets and therapeutic mechanisms, while significantly expanding our clinical and business opportunities. With this data outcome from our glaucoma program, we will now focus 100% of our efforts on broadening our metabolic clinical pipeline,&#8221; said Punit Dhillon, Skye&#8217;s CEO and Chair. &#8220;We believe that Nimacimab&#8217;s unique mechanism of peripheral CB1 inhibition positions it to potentially contribute to the need for higher-quality, sustainable weight loss and better treatments for co-morbid conditions amidst an </font><font style="color:#212121;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">incretin-biased </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">anti-obesity therapeutic landscape. We will look forward to sharing updates on this clinical program and advancing Nimacimab through to data in 2025.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Nimacimab</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nimacimab is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. Inhibition of CB1 has shown anti-fibrotic, anti-inflammatory, and metabolic mechanisms of action with potential to address a broad range of diseases with notable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unmet medical needs such as obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Skye Bioscience </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes. Backed by specialist life science investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for Nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of Nimacimab and a GLP-1R agonist. Clinical development of SBI-100 Ophthalmic Emulsion for glaucoma and ocular hypertension will be discontinued.  Please visit&#58; https&#58;&#47;&#47;www.skyebioscience.com</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CONTACTS</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Investor Relations</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">ir&#64;skyebioscience.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(858) 410-0266</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">LifeSci Advisors, Mike Moyer</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">mmoyer&#64;lifesciadvisors.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(617) 308-4306</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Media Inquiries</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">LifeSci Communications, Michael Fitzhugh</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">mfitzhugh&#64;lifescicomms.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(628) 234-3889</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">FORWARD LOOKING STATEMENTS</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including statements regarding our product development, business strategy, the timing of clinical trials and published findings, and expected operating runway. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management&#8217;s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including &#8220;anticipated,&#8221; &#8220;plans,&#8221; &#8220;goal,&#8221; &#8220;focus,&#8221; &#8220;aims,&#8221; &#8220;intends,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;challenge,&#8221; &#8220;predictable,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;may&#8221; or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company&#8217;s periodic filings with the Securities and Exchange Commission, including in the &#8220;Risk Factors&#8221; section of Skye&#8217;s most recent Annual Report on Form 10-K </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>skye-20240610.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5b56f1a-30f4-4661-b175-1f0050784193,g:1ece6a67-4871-47f8-9d23-a4b267bd419c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:skye="http://skyebioscience.com/20240610" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://skyebioscience.com/20240610">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="skye-20240610_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="skye-20240610_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="skye-20240610_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://skyebioscience.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>skye-20240610_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5b56f1a-30f4-4661-b175-1f0050784193,g:1ece6a67-4871-47f8-9d23-a4b267bd419c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://skyebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="skye-20240610.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://skyebioscience.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_665c5f81-6244-4b33-943d-18092a32b75f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_1b2e9fb0-de6e-4368-96a6-0ebced799749" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_665c5f81-6244-4b33-943d-18092a32b75f" xlink:to="loc_dei_DocumentInformationTable_1b2e9fb0-de6e-4368-96a6-0ebced799749" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>skye-20240610_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5b56f1a-30f4-4661-b175-1f0050784193,g:1ece6a67-4871-47f8-9d23-a4b267bd419c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_7857ba73-ee90-4949-8699-1a6a6acbbcce_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_e03cd480-2afc-4dd9-b0b3-03d3a32aed6e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_69a4d507-502f-4e3f-9200-6bbb9118de03_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dc6fe4e7-9f38-4238-a5ce-37e186afde2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4aacade8-8329-40b6-a572-16c7d3c70605_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b73f0617-ffc2-4c38-ae2f-e8d20bd1d58c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_144dbc6f-1201-4db8-90c5-e8cd999186f4_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_965b1ddb-c8ac-424b-919c-9b0ba6b01c67_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7e320845-e89c-4fc7-87dd-8c8f72d611c1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2d9b66c8-cdb2-4dd0-9d7e-bf5730932f88_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_53147ee9-65e1-4962-94a3-9b107adf143b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_fa834e37-6feb-408d-8241-b039ba30624d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_bacc49f3-97f9-47e3-b97a-5c887444c4df_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4b5f524c-4f59-4545-9336-036117f2458b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d67d9b9f-1c87-4a87-bcfb-7f4f16ef488e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_e6c65faa-a1c4-44d7-9f09-a927779aa9fd_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_18b055b6-910f-42bc-85df-d337ff28f69c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b42a35d3-5104-4801-973e-3ac2535068da_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1f91e5dd-11d1-4b00-ad37-e35bbe352fab_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d0e0994b-08e8-4973-999a-a74ece723c62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_37f46ce1-01d6-4da5-8de2-3bf17c76f08f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_021c2f35-acee-40b5-a74f-0ad923da9ace_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>skye-20240610_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5b56f1a-30f4-4661-b175-1f0050784193,g:1ece6a67-4871-47f8-9d23-a4b267bd419c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://skyebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="skye-20240610.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://skyebioscience.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1c5c4964-97e4-4241-85e0-faccbe4feee9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_DocumentType_1c5c4964-97e4-4241-85e0-faccbe4feee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2fd8c98f-a4a6-4684-b865-da31d9411ddc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_DocumentPeriodEndDate_2fd8c98f-a4a6-4684-b865-da31d9411ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3828c8f9-9f82-46a0-8fe7-9a4a6fc66df2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityRegistrantName_3828c8f9-9f82-46a0-8fe7-9a4a6fc66df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a58b12f5-ee46-4f7a-bf43-9b89d41ed086" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a58b12f5-ee46-4f7a-bf43-9b89d41ed086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1f759d49-97cb-49d1-948a-e2d7172be636" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityFileNumber_1f759d49-97cb-49d1-948a-e2d7172be636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5d014f89-d9ef-47b4-a493-94b4860d3051" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityTaxIdentificationNumber_5d014f89-d9ef-47b4-a493-94b4860d3051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2b5603a4-d13f-461a-a689-0e1332ad349a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityAddressAddressLine1_2b5603a4-d13f-461a-a689-0e1332ad349a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_87f960d7-1c2f-488b-bfd8-10200d8eaeb9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityAddressAddressLine2_87f960d7-1c2f-488b-bfd8-10200d8eaeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7abd5346-4418-4881-8253-7022601352f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityAddressCityOrTown_7abd5346-4418-4881-8253-7022601352f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_21ddf602-5ab7-4850-a860-4404647c490b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityAddressStateOrProvince_21ddf602-5ab7-4850-a860-4404647c490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f0eef392-45bb-40d5-b4ee-79615a0889e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityAddressPostalZipCode_f0eef392-45bb-40d5-b4ee-79615a0889e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c8f1de20-f67b-4d3a-8c51-c23efaf6bb11" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_CityAreaCode_c8f1de20-f67b-4d3a-8c51-c23efaf6bb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_915ca559-7082-4d11-a671-a1aa2dc29e82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_LocalPhoneNumber_915ca559-7082-4d11-a671-a1aa2dc29e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_83915f9b-d367-4def-ba6a-ba9ca0976464" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_WrittenCommunications_83915f9b-d367-4def-ba6a-ba9ca0976464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c5aca0ee-2219-4698-acdc-475008b31d44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_SolicitingMaterial_c5aca0ee-2219-4698-acdc-475008b31d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_16a628a3-8240-47cb-9742-636a0f499fa8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_PreCommencementTenderOffer_16a628a3-8240-47cb-9742-636a0f499fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9ce719dd-145e-45d0-8c17-9b7f911ffed5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9ce719dd-145e-45d0-8c17-9b7f911ffed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d149a686-555c-41c2-a50d-c3647cd459fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityEmergingGrowthCompany_d149a686-555c-41c2-a50d-c3647cd459fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_321ba5d1-ebcd-4fbc-9e6c-54b7211e553d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_AmendmentFlag_321ba5d1-ebcd-4fbc-9e6c-54b7211e553d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_098db051-3ab5-4840-9789-50c12723a118" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_EntityCentralIndexKey_098db051-3ab5-4840-9789-50c12723a118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_1b2e9fb0-de6e-4368-96a6-0ebced799749" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bc3637b-a143-427f-912c-55d2b3a5c159" xlink:to="loc_dei_DocumentInformationTable_1b2e9fb0-de6e-4368-96a6-0ebced799749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_665c5f81-6244-4b33-943d-18092a32b75f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1b2e9fb0-de6e-4368-96a6-0ebced799749" xlink:to="loc_dei_DocumentInformationLineItems_665c5f81-6244-4b33-943d-18092a32b75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139836395859392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Jun. 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 10,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SKYE BIOSCIENCE, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-55136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0692882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11250 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">410-0266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M %8V-W#DY=J] ,]72MFWCCN%58?HT;]02P,$%     @ <TO*6)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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MK(0* Y1OJA65UY**+2?=T>M,[Q\FCUI&Z]Q*N??P2K8<<XY_M/P!4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( '-+RE@'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ <TO*
M6.<RH ;O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ <TO*6)E<G",0!@  G"<  !,              ( !
MS0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !S2\I879AL'/0#
M  !0#P  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ <TO*6)^@&_"Q @  X@P   T              ( !
M. P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !S2\I8EXJ[',     3 @
M"P              @ $4#P  7W)E;',O+G)E;'-02P$"% ,4    " !S2\I8
M&445]3<!   G @  #P              @ ']#P  >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ <TO*6"0>FZ*M    ^ $  !H              ( !81$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ <TO*6&60
M>9(9 0  SP,  !,              ( !1A(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  D!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>20</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="skye-20240610.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://skyebioscience.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="skye-20240610.htm">skye-20240610.htm</File>
    <File>skye-20240610.xsd</File>
    <File>skye-20240610_def.xml</File>
    <File>skye-20240610_lab.xml</File>
    <File>skye-20240610_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "skye-20240610.htm": {
   "nsprefix": "skye",
   "nsuri": "http://skyebioscience.com/20240610",
   "dts": {
    "inline": {
     "local": [
      "skye-20240610.htm"
     ]
    },
    "schema": {
     "local": [
      "skye-20240610.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "skye-20240610_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "skye-20240610_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "skye-20240610_pre.xml"
     ]
    }
   },
   "keyStandard": 20,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 20
   },
   "report": {
    "R1": {
     "role": "http://skyebioscience.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "skye-20240610.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "skye-20240610.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001516551-24-000059-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001516551-24-000059-xbrl.zip
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M?;XT"C[1DY9LNPQCJ9B&+IO/NZVQ4UZ8>#8\/'C8CA&^S9JNM5P&!%_WJ5H
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MA\W/%-A4BUJX[C&SOWL&9^M?M<#60%W KF=T5J3B1R#I.I9Z"K&D#&0[.R]
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ME#%" KFAN%-O'"Q;*;P.ZB3LP;I*)+"9N%*ZNXQ]B3U8<;SH'507#YA[N1T
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M'IKCCWA 6)G@K[70@;Y=.Y/W.R9:D<8[*+H,M(Z*S@'^+<VE>>M4QHFDG&J
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M-C$P+GAS9%!+ 0(4 Q0    ( '-+REB@4';/NP(  %()   5
M  "  74D  !S:WEE+3(P,C0P-C$P7V1E9BYX;6Q02P$"% ,4    " !S2\I8
M=[:DT^L)  "A50  %0              @ %C)P  <VMY92TR,#(T,#8Q,%]L
M86(N>&UL4$L! A0#%     @ <TO*6$"MUEVJ!@  3#$  !4
M ( !@3$  '-K>64M,C R-# V,3!?<')E+GAM;%!+!08     !@ & ),!  !>
%.      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>skye-20240610_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="skye-20240610.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
        </entity>
        <period>
            <startDate>2024-06-10</startDate>
            <endDate>2024-06-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-19">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-20">0001516551</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-06-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">SKYE BIOSCIENCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-55136</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">45-0692882</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">11250 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">410-0266</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-18">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
